These experiments demonstrated that SEMA3A-overexpressing cancer cells demonstrated reduced breast tumour growth due to the higher activity of PTEN and MelCAM and reduced expression of vascular endothelial growth factor (VEGF) and phosphorylated FOXO3A. The gene discussed is PTEN; the disease is cancer.